Autism Spectrum Disorder Market Size and Trend Report including Epidemiology, Disease Management, Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2021 - 2031 (original) (raw)

Figure 1: Global sales forecast by country for ASD in 2021 and 2031

Figure 2: Analysis of the company portfolio gap in ASD during the forecast period

Figure 3: Competitive assessment of the late-stage pipeline agents that GlobalData expects to be licensed for the treatment of ASD during the forecast period

Figure 4: 7MM, diagnosed prevalence of ASD, both sexes, %, all ages, 2021

Figure 5: 7MM, sources used and not used to forecast the total prevalent cases of ASD

Figure 6: 7MM, sources used and not used to forecast the diagnosed prevalent cases of ASD

Figure 7: 7MM, total prevalent cases of ASD, N, men and women, all ages, 2021

Figure 8: 7MM age-specific total prevalent cases of ASD, N, men and women, 2021

Figure 9: 7MM total prevalent cases of ASD by sex, N, all ages, 2021

Figure 10: 7MM diagnosed prevalent cases of ASD, N, men and women, all ages, 2021

Figure 11: 7MM age-specific diagnosed prevalent cases of ASD, N, men and women, all ages, 2021

Figure 12: 7MM diagnosed prevalent cases of ASD by sex, N, all ages, 2021

Figure 13: Unmet needs and opportunities in ASD

Figure 14: Overview of the development pipeline in ASD

Figure 15: Key late-stage trials for the promising pipeline agents that GlobalData expects be licensed for ASD in the 7MM during the forecast period

Figure 16: Competitive assessment of the marketed and pipeline drugs benchmarked against the SOC, Abilify (aripiprazole)

Figure 17: Analysis of the company portfolio gap in ASD during the forecast period

Figure 18: Global (7MM) sales forecast by country for ASD in 2021 and 2031

Figure 19: Global (7MM) sales forecast by class for ASD in 2021 and 2031

Figure 20: Sales forecast by class for ASD in the US in 2021 and 2031

Figure 21: Sales forecast by class for ASD in the 5EU in 2021 and 2031

Figure 22: Sales forecast by class for ASD in Japan in 2021 and 2031